An integral pharmacokinetic analysis of piperacillin and tazobactam in plasma and urine in critically ill patients

E Wallenburg, R Ter Heine, JA Schouten… - Clinical …, 2022 - Springer
Abstract Background and Objectives Although dose optimization studies have been
performed for piperacillin and tazobactam separately, a combined integral analysis is not yet …

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic …

E Asín-Prieto, A Rodríguez-Gascón… - Journal of …, 2014 - academic.oup.com
Objectives To evaluate the pharmacokinetics of piperacillin/tazobactam in critically ill
patients undergoing continuous renal replacement therapy (CRRT) and to assess the …

Piperacillin-tazobactam in intensive care units: a review of population pharmacokinetic analyses

I El-Haffaf, JA Caissy, A Marsot - Clinical pharmacokinetics, 2021 - Springer
Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Pharmacokinetics of an extended 4‐hour infusion of piperacillin‐tazobactam in critically ill patients undergoing continuous renal replacement therapy

DK Awissi, A Beauchamp, E Hébert… - … : The Journal of …, 2015 - Wiley Online Library
Study Objective To evaluate the pharmacokinetic and pharmacodynamic profiles of
piperacillin‐tazobactam administered as a 4‐hour infusion in critically ill patients undergoing …

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with nosocomial infections

R Chen, Q Qian, M Sun, C Qian, S Zou, M Wang… - European journal of …, 2016 - Springer
Objective The study was to establish a population pharmacokinetic (PPK) model of
piperacillin (PIP) and tazobactam (TAZ) that explain pharmacokinetic variability and to …

Population pharmacokinetics of piperacillin following continuous infusion in critically ill patients and impact of renal function on target attainment

V Klastrup, A Thorsted, M Storgaard… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Pharmacokinetic changes are often seen in patients with severe infections. Administration
by continuous infusion has been suggested to optimize antibiotic exposure and …

Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375 G Q4H and 4.5 G Q6H

HM Mattoes, B Capitano, MK Kim, D Xuan… - Chemotherapy, 2002 - karger.com
When piperacillin/tazobactam has been used to treat hospitalized patients with serious
infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has …

Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion

C Buck, N Bertram, T Ackermann, T Sauerbruch… - International journal of …, 2005 - Elsevier
In the present study 24 hospitalized patients requiring empirical antibiotic treatment were
randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination …

Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered?

MG Andersen, A Thorsted, M Storgaard… - Antimicrobial agents …, 2018 - Am Soc Microbiol
Sufficient antibiotic dosing in septic patients is essential for reducing mortality. Piperacillin-
tazobactam is often used for empirical treatment, but due to the pharmacokinetic (PK) …

A population pharmacokinetics and pharmacodynamic approach to optimize tazobactam activity in critically ill patients

SN Kalaria, M Gopalakrishnan… - Antimicrobial agents and …, 2020 - Am Soc Microbiol
The percentage of the time that the free drug concentration remains above a concentration
threshold (% fT> concentration threshold) has frequently been identified to be the optimal …